Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (IRG270459)
Instituto de Salud Carlos III (PI16/00066)
Ministerio de Ciencia e Innovación (IEDI-2015-00638)
Basque Foundation for Health Research (BIOEF, BIO13/CI/005)
Received: 31 July 2018
Accepted: 21 November 2018
First Online: 29 November 2018
Ethics approval and consent to participate
: Cell line 531MII was obtained from a metastatic bone implant of an adult who provided informed consent for participation in our research protocol. The written informed consent was specifically for deriving cell lines from primary osteosarcoma tumors, and was approved by the Ethics Committee of Clinica Universidad de Navarra, following national requirements. After the death, both parents gave oral agreement so that cell line could be share for research purposes under a MTA.All the procedures involving animals performed in this study were carried out in accordance with the guidelines of the European Communitiy (Council Directive 2010/63/UE) and the Spanish Government (Real Decreto 53/2013) and were approved by the Ethics Committee for Animal Experimentation of the University of Navarra (protocols 065–13 and 160–11).
: Not applicable.
: The authors declare that they have no competing interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.